M2 Archive: Preview


You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.


Calquence granted US Breakthrough Therapy Designation for chronic lymphocytic leukaemia

Designation based on positive results from two Phase III trials

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Calquence (acalabrutinib) as a monotherapy treatment for...  


If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search